奥曲肽联合苯扎贝特、低分子肝素钙治疗高脂血症胰腺炎的临床效果

Clinical Effect of Octreotide Combined with Benzabate and Low Molecular Heparin Calcium on Hyperlipidemic Pancreatitis

目的:探讨奥曲肽联合苯扎贝特、低分子肝素钙治疗高脂血症胰腺炎的临床效果及对炎症因子水平的影响。方法:选取2017年4月-2019年5月笔者所在医院收治的高脂血症胰腺炎患者80例。按随机数字表法将其均分为观察组和对照组。对照组采取苯扎贝特及低分子肝素钙治疗,观察组在对照组的基础上联合奥曲肽治疗。对比两组临床疗效;记录两组厌食、腹部疼痛及恶心呕吐等不良反应发生率;对比两组首次通气时间、胃肠减压时间及腹痛缓解时间等临床症状指标;对比两组CRP、IL-6及IL-33等炎症因子水平。结果:观察组患者治疗总有效率(97.50%)显著高于对照组患者的70.00%(P<0.05);观察患者不良反应总发生率(5.00%)显著低于对照组患者的25.00%(P<0.05);观察组患者首次通气时间、胃肠减压时间及腹痛缓解时间均早于对照组患者(P<0.05);两组患者CRP、IL-6及IL-33水平较治疗前均有所降低,但治疗后观察组患者各炎症因子水平均显著低于对照组(P<0.05)。结论:奥曲肽联合苯扎贝特、低分子肝素钙治疗高脂血症胰腺炎的临床疗效确切,能有效缓解患者临床症状,降低患者体内IL-33等炎性因子的表法水平,进而降低患者不适感。同时减少不良反应发生情况,具有较高的药物安全性,具有广阔的应用前景,值得临床运用与推广。

Objective:To investigate the clinical effect of Octreotide combined with benzabate and Low Molecular Heparin Calcium in the treatment of hyperlipidemic pancreatitis and its influence on inflammatory factors levels.Method:A total of 80 patients with hyperlipidemia pancreatitis admitted to our hospital from April 2017 to May 2019 were selected.They were divided into observation group and control group according to random number table method.The control group was treated with Benzabate and Low molecular weight heparin calcium,and the observation group was treated with Octreotide on the basis of the control group.The clinical efficacy of the two groups was compared.The incidence of anorexia,abdominal pain,nausea and vomiting was recorded.The first ventilation time,gastrointestinal decompression time and abdominal pain relief time were compared between the two groups.The levels of inflammatory factors such as CRP,IL-6 and IL-33 were compared between the two groups.Result:The total effective rate (97.50%) in the observation group was significantly higher than 70.00% in the control group (P<0.05).The total incidence of adverse reactions in the observed patients (5.00%) was significantly lower than 25.00% in the control group (P<0.05).The first ventilation time,gastrointestinal decompression time and abdominal pain relief time in the observation group were all lower than those in the control group (P<0.05).The levels of CRP,IL-6 and IL-33 in both groups were lower than those before treatment,but the levels of all inflammatory factors in the observation group were significantly lower than those in the control group after treatment (P<0.05).Conclusion:Octreotide combined with Benzodiazepine and Low Molecular Weight Heparin Calcium in the treatment of hyperlipidemia pancreatitis has a definite clinical effect,can effectively alleviate the clinical symptoms of patients,reduce the level of IL-33 and other inflammatory factors in the body,and thus reduce the patient’s discomfort.At the same time,it can reduce the occurrence of adverse reactions,which has higher drug safety and broad application prospect,and is worthy of clinical application and promotion.